ArriVent BioPharma, Inc. (AVBP) Stock
4 of the hedge funds AlphaScala tracks reported AVBP in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $30.29M.
Which hedge funds own AVBP?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 872K | $30.29M | +136% |
| Point72 Steve Cohen | 567K | $19.69M | -24% |
| Millennium Management Israel Englander | 439K | $15.24M | +3% |
| Citadel Ken Griffin | 157K | $5.45M | -6% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →AVBP price chart
Powered by TradingViewWhat does ArriVent BioPharma, Inc. do?
Arrivent Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of differentiated medicines to address unmet medical needs in patients with difficult-to-treat diseases, starting with cancers. Its lead development candidate, firmonertinib, a tyrosine kinase inhibitor, is being evaluated in multiple clinical trials for various epidermal growth factor receptor mutations in non-small cell lung cancer, including a Phase 3 trial for exon 20 insertion mutations and Phase 1b trials for activating mutations such as P-loop and alpha-c-helix compressing mutations. The company is also advancing ARR-217, an antibody drug conjugate targeting gastrointestinal cancers, and ARR-002 for solid tumors. Arrivent Biopharma Inc. leverages strategic collaborations with partners like Shanghai Allist Pharmaceuticals, Aarvik Therapeutics, Beijing InnoCare Pharma Tech, Jiangsu Alphamab Biopharmaceuticals, and Lepu Biopharma to accelerate global development of innovative oncology therapeutics. Founded in 2021 and headquartered in Newtown Square, Pennsylvania, it operates within the biotechnology sector of pharmaceuticals and biotech, emphasizing novel therapies like next-generation antibody drug conjugates.